Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 21148526.
- Also identified by DOI 10.1093/cid/ciq072.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin during an 8-week period. The treatment was well tolerated, and all patients were healed by 12 months after initiation of therapy without relapse.
Medical subject headings
- Anti-Bacterial Agents
- Buruli Ulcer
- Mycobacterium ulcerans